Podocalyxin tumor-restricted glycoepitope (PODXL glycoepitope)

Podocalyxin (PODXL) is a type-I transmembrane sialomucin that plays a critical role in maintaining the architecture of renal podocytes and vascular endothelial cells (UniProt: O00592). In many aggressive cancers, PODXL is significantly upregulated and exhibits altered O-glycosylation within its extracellular mucin domain, creating a tumor-restricted glycoepitope (PubMed: 32814775). This specific glycoform is absent in healthy tissues, providing a unique therapeutic window for targeting malignant cells while sparing normal ones. The epitope is involved in promoting epithelial-to-mesenchymal transition (EMT), cell migration, and metastasis by modulating cell-cell adhesion and activating signaling pathways like PI3K/Akt (PubMed: 27433825). Therapeutic strategies focusing on this target include monoclonal antibodies such as PODO-2 and its derivative antibody-drug conjugates (ADCs), which aim to deliver cytotoxic payloads directly to the tumor microenvironment. By targeting the mucin domain's specific glycosylation, these therapies can effectively inhibit the pro-invasive properties of cancer cells and induce targeted cell death. This target is particularly relevant in colorectal, pancreatic, and high-grade serous ovarian cancers where high PODXL expression correlates with poor patient prognosis (PubMed: 28235104).

Other names

Tumor-specific podocalyxinPODXL mucin domain glycoepitopePODO-2 epitopePodocalyxin-like protein 1PCLP-1

Targeted delivery of cytotoxic agents via antibody-drug conjugates or antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing the specific glycoform.